Cannabis Bioscience Revenue Plunges 69% to $77K in H1 FY2026
Cannabis Bioscience International Holdings, a Colorado-based cannabis holding company, reported revenue of $77,466 for the six months ending November 30, 2025, down 69% from $253,135 in the prior-year period. The company posted a net loss of $199,612.
Cannabis Bioscience International Holdings, a Colorado-based cannabis holding company, reported revenue of $77,466 for the six months ending November 30, 2025, down 69% from $253,135 in the same period a year earlier. The company posted a net loss of $199,612 for the half-year, compared to a loss of $155,833 in the prior year. Read more earnings reports.
For the three months ending November 30, 2025, revenue totaled $53,266, a 28% decline from $74,248 in the year-ago quarter. The quarterly net loss widened to $116,966 from $79,528 a year earlier.
Operating expenses for the six-month period reached $229,484, down 42% from $394,201 in the prior-year period. Labor and related expenses dropped to $78,661 from $100,169 year-over-year. Cost of revenue for the half-year increased to $18,643 from $16,165 in the prior year.
The company reported an operating loss of $170,661 for the six months, compared to a loss of $157,231 in the prior-year period. Gross profit for the half-year totaled $58,823, down 75% from $236,970 a year earlier.
Cash and restricted cash fell sharply to $132 as of November 30, 2025, down from $12,952 six months earlier. The company burned through $109,205 in cash from operations during the six-month period, compared to $109,205 in the prior-year period.
Total assets declined to $22,131 at period-end from $31,880 six months prior. Accounts receivable increased to $21,811 from $6,380 over the same span.
Total liabilities rose to $1,385,326 from $1,195,463 six months earlier. Current liabilities climbed to $1,135,826 from $945,963. Long-term debt remained unchanged at $249,500.
Stockholders' deficit deepened to negative $1,363,195 from negative $1,163,583 at the end of the prior fiscal year. The company reported 11,626,749,347 common shares outstanding as of November 30, 2025.
Basic and diluted loss per share for the six months was $0.000017, compared to $0.0000015 in the prior-year period.
Financial Summary
| Period | Revenue | Net Loss | Operating Loss | Cash Flow from Operations |
|---|---|---|---|---|
| Six months ending Nov 30, 2025 | $77,466 | ($199,612) | ($170,661) | ($109,205) |
| Six months ending Nov 30, 2024 | $253,135 | ($155,833) | ($157,231) | ($102,503) |
| Three months ending Nov 30, 2025 | $53,266 | ($116,966) | ($95,877) | — |
| Three months ending Nov 30, 2024 | $74,248 | ($79,528) | ($59,627) | — |
Balance Sheet Highlights
| Item | As of Nov 30, 2025 | As of May 31, 2025 |
|---|---|---|
| Total Assets | $22,131 | $31,880 |
| Cash & Restricted Cash | $132 | $12,952 |
| Total Liabilities | $1,385,326 | $1,195,463 |
| Stockholders' Deficit | ($1,363,195) | ($1,163,583) |
| Long-Term Debt | $249,500 | $249,500 |